ALK Biomarkers
News and reporting on ALK biomarkers.
FDA Approves Xcovery's Ensacove for ALK-Positive NSCLC
In a Phase III trial, patients on Ensacove lived almost twice as long without disease progression or death as those on another ALK inhibitor.
Roche Sees Strong Demand for Elevidys Gene Therapy Amid Steady Q3 Pharmaceutical Revenue Growth
Premium
About 500 children worldwide have received the gene therapy, including some families traveling abroad to gain access to it.
UK's NICE Recommends Alecensa as Adjuvant Treatment for ALK-Positive Lung Cancer
The agency based its decision on results from the Phase III ALINA trial in which Alecensa improved disease-free survival in ALK-positive NSCLC patients.
Lung Cancer Groups Seek Public Comment on Updated Biomarker Testing Guidelines
Updated guidelines recommend certain biomarker tests for early- and late-stage lung cancer at the time of diagnosis.
Roche Reports 5 Percent CER Growth in Pharmaceutical Sales Driven by Strong Phesgo Uptake
In the first half of the year, sales of the injectable formulation of HER2-targeted agent grew 60 percent at CER, compared to H1 2023.